As of 2025-05-12, the EV/EBITDA ratio of Intra-Cellular Therapies Inc (ITCI) is -118.23. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ITCI's latest enterprise value is 13,739.84 mil USD. ITCI's TTM EBITDA according to its financial statements is -116.21 mil USD. Dividing these 2 quantities gives us the above ITCI EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.6x - 12.0x | 9.6x |
| Forward P/E multiples | 10.1x - 17.0x | 13.6x |
| Fair Price | (8.12) - (10.23) | (9.72) |
| Upside | -106.2% - -107.8% | -107.4% |
| Date | EV/EBITDA |
| 2025-04-01 | -118.23 |
| 2025-03-31 | -118.28 |
| 2025-03-28 | -118.17 |
| 2025-03-27 | -118.12 |
| 2025-03-26 | -118.06 |
| 2025-03-25 | -118.07 |
| 2025-03-24 | -118.07 |
| 2025-03-21 | -118.03 |
| 2025-03-20 | -117.98 |
| 2025-03-19 | -117.92 |
| 2025-03-18 | -117.84 |
| 2025-03-17 | -117.84 |
| 2025-03-14 | -117.67 |
| 2025-03-13 | -117.76 |
| 2025-03-12 | -117.66 |
| 2025-03-11 | -117.65 |
| 2025-03-10 | -117.66 |
| 2025-03-07 | -117.65 |
| 2025-03-06 | -117.66 |
| 2025-03-05 | -117.61 |
| 2025-03-04 | -117.65 |
| 2025-03-03 | -117.69 |
| 2025-02-28 | -114.87 |
| 2025-02-27 | -114.91 |
| 2025-02-26 | -115.10 |
| 2025-02-25 | -115.21 |
| 2025-02-24 | -115.21 |
| 2025-02-21 | -115.23 |
| 2025-02-20 | -115.18 |
| 2025-02-19 | -115.23 |
| 2025-02-18 | -114.65 |
| 2025-02-14 | -114.52 |
| 2025-02-13 | -114.74 |
| 2025-02-12 | -114.66 |
| 2025-02-11 | -114.28 |
| 2025-02-10 | -113.88 |
| 2025-02-07 | -113.78 |